Skip to main content
Atrás
ABUS logo

Arbutus Biopharma Corporation

Calidad de datos: 100%
ABUS
NASDAQ Healthcare Biotechnology
$4.42
▲ $0.18 (4.25%)
Cap. Mercado: 850.07M
Rango del Día
$4.25 $4.60
Rango de 52 Semanas
$2.71 $5.10
Volumen
7,584,933
Promedio 50D / 200D
$4.34 / $4.10
Cierre Anterior
$4.24

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E -25.4 0.4
P/B 11.1 2.9
ROE % -38.5 3.7
Net Margin % -237.9 3.8
Rev Growth 5Y % 6.4 10.0
D/E 0.0 0.2

Puntos Clave

Revenue grew 6.40% annually over 5 years — modest growth
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -39.64M
PEG of 0.50 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 121.81%
Capital efficient — spends only 0.00% of revenue on capex

Crecimiento

Revenue Growth (5Y)
6.40%
Revenue (1Y)128.21%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-38.52%
ROIC-37.01%
Net Margin-237.88%
Op. Margin-270.96%

Seguridad

Debt / Equity
0.01
Current Ratio15.73
Interest Coverage393.40

Valoración

P/E Ratio
-25.37
P/B Ratio11.10
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 128.21% Revenue Growth (3Y) -11.89%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 6.40% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14.08M Net Income (TTM) -33.50M
ROE -38.52% ROA -35.41%
Gross Margin 0.00% Operating Margin -270.96%
Net Margin -237.88% Free Cash Flow (TTM) -39.64M
ROIC -37.01% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 15.73
Interest Coverage 393.40 Dividend Yield 0.00%
Valuation
P/E Ratio -25.37 P/B Ratio 11.10
P/S Ratio 60.36 PEG Ratio 0.50
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 850.07M Enterprise Value 832.81M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.08M 6.17M 18.14M 39.02M 10.99M
Net Income -33.50M -69.92M -72.85M -69.46M -76.25M
EPS (Diluted) -0.17 -0.38 -0.44 -0.46 -0.73
Gross Profit 0.0 6.17M 18.14M 39.02M 10.99M
Operating Income -38.16M -76.32M -78.10M -65.46M -73.52M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 94.62M 131.71M 144.40M 195.42M 204.49M
Total Liabilities 18.04M 34.34M 38.38M 58.57M 35.05M
Shareholders' Equity 76.58M 97.37M 106.02M 136.85M 169.44M
Total Debt 746,000.0 1.29M 8.72M 12.55M 18.91M
Cash & Equivalents 18.01M 36.33M 26.29M 30.78M 109.28M
Current Assets 94.46M 127.32M 132.03M 151.14M 160.66M
Current Liabilities 6.01M 15.62M 22.49M 32.86M 11.22M